Clinical Trial Detail

NCT ID NCT04052555
Title Testing the Addition of an Anti-cancer Drug, M6620, to the Usual Treatment (Radiation Therapy) for Chemotherapy-Resistant Triple-Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors National Cancer Institute (NCI)
Indications

Her2-receptor negative breast cancer

triple-receptor negative breast cancer

Therapies

Berzosertib

Age Groups: adult senior

Additional content available in CKB BOOST